The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
Journal Title: Journal of Surgery : Concepts & Practice - Year 2024, Vol 29, Issue 5
Abstract
Bone-modifying agents (BMAs), including bisphosphonate (BP) and denosumab, can reduce bone-related events caused by breast cancer bone metastasis. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update” was published in Journal of Clinical Oncology in January 2022. The new “2022 version Guideline” suggested that the use of BP should be discussed for all postmenopausal patients with early breast cancer who are indicated for adjuvant therapy. Recommended drugs included zoledronate, clodronate, and ibandronate, and the recommended duration of BP was 2-3 years. Owing to the inconsistent results of the ABCSG-18 and D-CARE trials and the lack of data directly comparing denosumab with BP in early breast cancer, the use of denosumab in adjuvant therapy was not recommended. In conclusion, the role of BP in the adjuvant treatment of early breast cancer has been further affirmed, while the value of denosumab remains unclear.
Authors and Affiliations
Yujie LU, Siji ZHU
Keywords
Related Articles
- EP ID EP761794
- DOI 10.16139/j.1007-9610.2024.05.07
- Views 13
- Downloads 0
<![CDATA[Diagnosis, treatment and full-process surveillance of early rectal cancer]]>
<![CDATA[Early rectal cancer is defined as any size of rectal epithelial tumor with infiltration depth limited to the mucosa and submucosa, regardless of with or without lymph node metastasis. Local resection is one of t...
Papillary thyroid microcarcinoma should not be used as the basis for postoperative 131I therapy
[Objective] To analyze the clinicopathological data of patients with papillary thyroid microcarcinoma (PTMC) and papillary thyroid non-microcarcinoma (non-PTMC) who received 131I therapy retrospectively, and compare th...
The strategy of extrahepatic organs management in early period after adult liver transplantation
With the improvements in surgical technique, the indications for liver transplantation(LT) are being expanded to more complex and severe patients, who not only have liver function in the terminal stage, but also extrahep...
Management of in-stent restenosis after iliofemoral venous stenting
Iliofemoral venous stent placement (IVS) is currently the first-line treatment for various acute and chronic deep vein obstruction diseases, effectively improving clinical symptoms in patients. However, in-stent restenos...
Current status and development of laparoscopic hepatectomy